We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Edesa Biotech Inc | NASDAQ:EDSA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.1025 | 2.30% | 4.5549 | 4.43 | 4.93 | 4.83 | 4.40 | 4.56 | 4,358 | 00:44:03 |
As filed with the
Securities and Exchange Commission on April 23, 2021
|
Registration No.
333-
|
British Columbia, Canada
(State
or other jurisdiction of incorporation or
organization)
|
N/A
(I.R.S.
Employer Identification No.)
|
100 Spy Court
Markham, Ontario, Canada
(Address
of principal executive offices)
|
L3R 5H6
(Zip
Code)
|
Large accelerated filer
|
☐
|
|
|
Smaller reporting company
|
☒
|
Non-accelerated filer
|
☒
|
|
|
Accelerated filer
|
☐
|
|
|
|
|
Emerging growth company
|
☒
|
Title of Securities
To Be Registered
|
Amount To Be
Registered (1)
|
Proposed Maximum
Offering Price
Per Share (2)
|
Proposed Maximum
Aggregate Offering
Price (2)
|
Amount Of
Registration Fee
|
Common Shares, no par value per share $0.001 per share
|
1,497,000(3)
|
$5.10
|
$7,634,700
|
$833
|
Exhibit
|
|
Incorporated by Reference
|
Filed
|
|||
Number
|
Exhibit Description
|
Form
|
File Number
|
Exhibit
|
Filing Date
|
Herewith
|
|
|
|
|
|
|
|
Opinion
of Fasken Martineau Dumoulin LLP
|
|
|
|
|
X
|
|
Edesa
Biotech, Inc. 2019 Equity Incentive Compensation Plan
|
8-K
|
001-37619
|
10.1
|
10/25/2019
|
|
|
Amendment
No. 1 to Edesa Biotech, Inc. 2019 Equity Incentive Compensation
Plan
|
8-K
|
001-37619
|
10.1
|
4/23/2021
|
|
|
Consent
of Fasken Martineau Dumoulin LLP (included in Exhibit
5.1)
|
|
|
|
|
X
|
|
Consent
of Independent Registered Public Accounting Firm
|
|
|
|
|
X
|
|
Power
of Attorney (included on signature page)
|
|
|
|
|
X
|
|
EDESA BIOTECH, INC.
(Registrant)
|
|
|
|
|
|
|
|
By:
|
/s/ Michael
Brooks
|
|
|
|
Michael
Brooks
|
|
|
|
President
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Pardeep Nijhawan
|
|
Director, Chief Executive Officer and Corporate
|
|
April 23, 2021
|
Pardeep Nijhawan
|
|
Secretary (Principal Executive Officer)
|
|
|
|
|
|
|
|
/s/ Kathi Niffenegger
|
|
Chief Financial Officer
|
|
April 23, 2021
|
Kathi Niffenegger
|
|
(Principal Financial and Accounting Officer)
|
|
|
|
|
|
|
|
/s/ Lorin Johnson
|
|
Director
|
|
April 23, 2021
|
Lorin Johnson
|
|
|
|
|
|
|
|
|
|
/s/ Sean McDonald
|
|
Director
|
|
April 23, 2021
|
Sean McDonald
|
|
|
|
|
|
|
|
|
|
/s/ Frank Oakes
|
|
Director
|
|
April 23, 2021
|
Frank Oakes
|
|
|
|
|
|
|
|
|
|
/s/ Paul Pay
|
|
Director
|
|
April 23, 2021
|
Paul Pay
|
|
|
|
|
|
|
|
|
|
/s/ Carlo Sistilli
|
|
Director
|
|
April 23, 2021
|
Carlo Sistilli
|
|
|
|
|
|
|
|
|
|
/s/ Peter van der Velden
|
|
Director
|
|
April 23, 2021
|
1 Year Edesa Biotech Chart |
1 Month Edesa Biotech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions